[ad_1] Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. 1. U.S. stocks were mostly higher on Friday. The S & P 500 was on track for a fifth positive week in a row. The broad market index topped…
[ad_1] Wall Street liked what it saw from GE Healthcare and Eli Lilly in their earnings reports, leading to a round of well-deserved price target bumps for the Club stocks. Analysts at four equity research firms boosted their price targets for GE Healthcare since the maker of MRI machines and other medical equipment on Tuesday…
[ad_1] Business at GE Healthcare Technologies capped off 2023 on a strong note despite ongoing concerns about China. That coupled with management’s upbeat view of this year propelled shares up more than 13% to over $83 each at session highs. That was their highest level since July 2023. The Club stock closed just under $82….
[ad_1] Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. 1. U.S. stocks were mixed Tuesday, on a muted performance from Big Tech. Citigroup strategists warned that tech stocks may stall out after monstrous gains. “The large consensus positioning…
[ad_1] Clorox – The consumer products giant saw a huge earnings beat. It’s also rebounding from last year’s cyberattack. “Things are back online, and there’s tremendous demand for their product,” Jim said Friday’s Morning Meeting rapid fire. Tesla – The EV leader issued a recall for 2.2 million cars over a warning light issue. Remember,…
[ad_1] Benchmark gauges notched all-time highs as stocks charged through a busy earnings season. [ad_2] Source link
[ad_1] Liselotte Sabroe | Afp | Getty Images Novo Nordisk on Wednesday reported better-than-expected 2023 earnings, as sales of its wildly popular anti-obesity and diabetes drugs continued to soar. The maker of weight loss drug Wegovy and diabetes drug Ozempic reported an increase in sales of 31% in Danish kroner and 36% at constant exchange…
[ad_1] We’re selling 95 shares of GE Healthcare at roughly $74. Following Wednesday’s trade, Jim Cramer’s Charitable Trust will own 1,150 shares of GEHC, reducing its weighting to 2.75% from 2.97%. The small trim we’re making in GE Healthcare with the stock up slightly in an otherwise rough tape does not change our belief in…
[ad_1] Olema Oncology could be a standout player in developing therapies for women’s cancers, particularly in breast cancer, according to Citi Research. Analyst Yigal Nochomovitz initiated the clinical-stage biotech company at a buy/high risk rating, saying it has potential in developing a “next-gen endocrine therapy.” His price target of $20 implies shares could surge more…
[ad_1] Hopes are sky-high for Eli Lilly’s recently launched weight loss drug Zepbound. Investors will be tuning into the company’s fourth quarter earnings call on Feb. 6, eager to hear more about how that rollout is going. One key statistic will be the number of commercial health insurers providing coverage of the drug, which was…
